Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Hiranuma O, Yamada T, Kanda H, Nakano T, Morimoto Y, Iwasaku M, Tokuda S, Takayama K.
Morimoto K, et al. Among authors: takayama k.
JTO Clin Res Rep. 2022 Jun 8;3(7):100353. doi: 10.1016/j.jtocrr.2022.100353. eCollection 2022 Jul.
JTO Clin Res Rep. 2022.
PMID: 35789793
Free PMC article.